ResearcherFirst Hospital of China Medical UniversityActive in the last 2 years

Shiyang Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8920-6221; OpenAlex author ID A5103209041. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper

Papers 2

ZNF263 cooperates with ZNF31 to promote the drug resistance and EMT of pancreatic cancer through transactivating RNF126. Co-author DOI 10.1002/jcp.31259 ↗
STMN2 overexpression promotes cell proliferation and EMT in pancreatic cancer mediated by WNT/β-catenin signaling. Last author DOI 10.1038/s41417-022-00568-w ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Mingrui Shao · 1 shared paper, 2023 · strength 0.24
- Paper STMN2 overexpression promotes cell proliferation and EMT in pancreatic cancer mediated by WNT/β-catenin signaling. DOI 10.1038/s41417-022-00568-w ↗
Weiwei Sheng · 1 shared paper, 2024 · strength 0.23
- Paper ZNF263 cooperates with ZNF31 to promote the drug resistance and EMT of pancreatic cancer through transactivating RNF126. DOI 10.1002/jcp.31259 ↗
Jiawei Zhang · 1 shared paper, 2024 · strength 0.23
- Paper ZNF263 cooperates with ZNF31 to promote the drug resistance and EMT of pancreatic cancer through transactivating RNF126. DOI 10.1002/jcp.31259 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.